Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777242 · ClinicalTrials.gov registry record · Phase 2
Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism
A Phase 2 study, sponsored by Antares Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02777242: Completed Phase 2 study, sponsored by Antares Pharma.
NCT02777242 is a Phase 2 study that has completed, run by Antares Pharma. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02777242, a Phase 2 study, has completed, sponsored by Antares Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.
Primary Outcome
Intended users were patients experiencing an adverse event that was considered to be a TEAE if the adverse event started on or after randomization, or existed prior to randomization and worsened in severity or relatedness to QST (QuickShot® Testosterone auto-injector) after randomization.
Interventions
- COMBINATION_PRODUCT Testosterone enanthate auto-injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT02777242 record still lists
NCT02777242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which Testosterone enanthate auto-injector is the first listed.
NCT02777242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02777242 about?
NCT02777242 is a clinical study titled "Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism". Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.
What is the current status of trial NCT02777242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2016-06. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02777242?
The interventions under investigation include: Testosterone enanthate auto-injector (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02777242?
This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02777242's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia